Author:
Madhavi Banda,Prasanna Jammula Surya,Rani Koduganti Rekha
Abstract
Context:
Connective tissue and alveolar bone loss in the region of the teeth is very frequent in inflammatory conditions like periodontitis (PD). As things go, apical movement of junctional epithelium deepens the periodontal pocket, ultimately tooth loss. Periodontal research advancements in biomarker assay prop up the risk by prior identification. Sclerostin, a skeletal marker, has been assessed to explore the intensity of PD and its effect after periodontal therapy.
Aims:
This study aimed to estimate serum sclerostin in patients affected with PD at the reference point and after periodontal therapy.
Settings and Design:
This was an interventional prospective study.
Materials and Methods:
Age-matched 30 PD patients, both male and female, were chosen. Clinical considerations, probing pocket depth and clinical attachment level, were assessed. Serum sclerostin levels were estimated using ELISA at baseline, 4 weeks after nonsurgical periodontal therapy (NSPT), and after 6 weeks of Surgical Periodontal Therapy (SPT).
Statistical Analysis Used:
Data were scrutinized by the SPSS version 23. A descriptive, paired t-test was done for values obtained at various intervals.
Results:
A positive correlation of sclerostin was found with severity of PD and was declined from starting point to NSPT and further to SPT (P<0.001). Both clinical as well as biochemical parameters reduced to NSPT and more significant reduction to SPT (< 0.001).
Conclusions:
Sclerostin severity was reduced in NSPT stage compared with baseline values, and furthermore reduced in SPT stage. Concluding that periodontal therapy is effective on biochemical marks, intensity and periodontal disease initiation can prior be detected by markers such as sclerostin.